<DOC>
	<DOCNO>NCT01548430</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , immunogenicity pharmacokinetics TTP4000 subject Alzheimer 's disease mild cognitive impairment .</brief_summary>
	<brief_title>A Safety Study TTP4000 Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Males female ≥ 50 year age . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . Weight ≥ 50 kg . Alzheimer 's disease accord DSMIVTR criterion score 20 26 Mini Mental State Exam . Subject must medical history least 6 month prior Screening ( confirm medical record ) diagnosis mild Alzheimer 's disease . Current evidence history within last 3 year neurological psychiatric illness could contribute dementia , include , limited : epilepsy , focal brain lesion , Parkinson 's disease , seizure disorder , head injury loss consciousness ; DSMIVTR criterion major psychiatric disorder , include psychosis , major depression , bipolar disorder . Participation dose another clinical trial , involve market investigational drug , within 30 day Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>